Estudo clínico controlado não-randomizado para avaliação da efetividade clínica e endoscópica na Doença de Crohn: Infliximabe versus Adalimumabe

Estudo clínico controlado não-randomizado para avaliação da efetividade clínica e endoscópica na Doença de Crohn: Infliximabe versus Adalimumabe

Submitted by JÚLIO PINHEIRO BAIMA (jpbaima@yahoo.com.br) on 2018-04-25T20:09:46Z No. of bitstreams: 1 Tese Doutorado Julio Pinheiro Baima 25 abril 2018.pdf: 1976761 bytes, checksum: fade6f9adcb14ae4ad0854e9274f5c9d (MD5) === Approved for entry into archive by Sulamita Selma C Colnago null (sulamit...

Full description

Bibliographic Details
Main Author:	Baima, Júlio Pinheiro [UNESP]
Other Authors:	Universidade Estadual Paulista (UNESP)
Language:	Portuguese
Published:	Universidade Estadual Paulista (UNESP) 2018
Subjects:	Doença de Crohn Terapia Biológica resposta clínica resposta endoscópica Crohn's disease biological therapy clinical response endoscopic response
Online Access:	http://hdl.handle.net/11449/153774

Similar Items

Avaliação da hemostasia na Doença de Crohn subclínica: papel da atividade endoscópica
by: Adriana Ribas Andrade
Published: (2018)

Avaliação da hemostasia na Doença de Crohn subclínica: papel da atividade endoscópica
by: Andrade, Adriana Ribas
Published: (2018)

Imunidade celular para o BCG na doença de Crohn = efeito de proteinas de soro de leite bovino enriquecido com TGF-beta
by: Oya, Vanessa
Published: (2010)

Adalimumab Dose-Escalation Therapy Is Effective in Refractory Crohn’s Disease Patients with Loss of Response to Adalimumab, Especially in Cases without Previous Infliximab Treatment
by: Taketo Suzuki, et al.
Published: (2019-02-01)

Efficacy of adalimumab in patients with crohn's disease and failure to infliximab therapy: a clinical series Eficacia de Adalimumab en pacientes con enfermedad de Crohn y fracaso previo a la terapia con Infliximab: resultados de una serie clínica
by: Patricia Cordero-Ruiz, et al.
Published: (2011-06-01)

Implementation of the simple endoscopic activity score in crohn's disease
by: Efstratios Koutroumpakis, et al.
Published: (2016-01-01)

Treatment persistence during therapeutic sequences with adalimumab and infliximab in the treatment of Crohn's disease
by: Carlos Taxonera, et al.

Indications of capsule endoscopy in Crohn's disease
by: Marisol Luján-Sanchis, et al.
Published: (2014-01-01)

Fecal calprotectin and C-reactive protein are associated with positive findings in capsule endoscopy in suspected small bowel Crohn's disease
by: Juan Egea-Valenzuela, et al.

ADALIMUMAB INDUCTION AND MAINTAINING REMISSION FOR CROHN’S DISEASE IN PATIENT WHO LOST RESPONSE TO INFLIXIMAB. Case report
by: Ivaylo Vazharov, et al.
Published: (2016-12-01)

Clinical efficacy of adalimumab versus infliximab and the factors associated with recurrence or aggravation during treatment of anal fistulas in Crohn's disease
by: Cheng-Chun Ji, et al.
Published: (2017-04-01)

Combination Therapy with Intensive Granulocyte and Monocyte Adsorptive Apheresis plus Adalimumab: Therapeutic Outcomes in 5 Cases with Refractory Crohn’s Disease
by: Keiji Ozeki, et al.
Published: (2012-12-01)

Adalimumab versus infliximab in treating post-operative recurrence of Crohn's disease: a national cohort study
by: Carmen-Monica Preda, et al.

Predictors of response to infliximab in patients with fistulizing Crohn's disease Factores predictivos de respuesta a infliximab en pacientes con enfermedad de Crohn fistulizante
by: M. Luna-Chadid, et al.
Published: (2004-06-01)

Long-Term Clinical Remission in Biologically Naïve Crohn’s Disease Patients with Adalimumab Therapy, Including Analyses of Switch from Adalimumab to Infliximab
by: Tsutomu Mizoshita, et al.
Published: (2016-06-01)

Refractory Duodenal Crohn's Disease Successfully Treated with Infliximab
by: You Lim Kim, et al.
Published: (2014-01-01)

A Novel Model Based on Serum Biomarkers to Predict Primary Non-Response to Infliximab in Crohn’s Disease
by: Li Li, et al.
Published: (2021-07-01)

Development and Validation of an Interleukin-6 Nomogram to Predict Primary Non-response to Infliximab in Crohn’s Disease Patients
by: Yueying Chen, et al.
Published: (2021-04-01)

Early intestinal obstruction after infliximab therapy in Crohn’s disease
by: Mitsuro Chiba, et al.
Published: (2019-08-01)

Fecal calprotectin as a biomarker of inflammatory lesions of the small bowel seen by videocapsule endoscopy
by: Juan Egea-Valenzuela, et al.
Published: (2015-04-01)

Adenocarcinoma de recto y ano en paciente con enfermedad de Crohn tratado con infliximab Adenocarcinoma of the rectum and anus in a patient with Crohn´s disease treated with infliximab
by: J. Egea Valenzuela, et al.
Published: (2010-08-01)

Successful Treatment of Postoperative Fistula with Infliximab in a Patient with Crohn's Disease
by: Seong Yeon Jeong, et al.
Published: (2014-01-01)

Serum Levels of Infliximab and Anti-Infliximab Antibodies in Brazilian Patients with Crohn’s Disease
by: Luis Eduardo Miani Gomes, et al.
Published: (2019-04-01)

Bioelectrical impedance analysis-based nomogram construction for predicting secondary loss of response to infliximab in bio-naïve Crohn’s disease patients
by: Chen Yueying, et al.
Published: (2021-10-01)

Adalimumab and azathioprine in the prevention of postoperative crohn’s disease recurrence
by: A. V. Poletova, et al.
Published: (2020-10-01)

Behandling med adalimumab vid Crohns sjukdom
by: Reimer Rasmusson, Ida
Published: (2009)

Clinical and Endoscopic Recurrence after Surgical Resection in Patients with Crohn's Disease
by: Yang Woon Lee, et al.
Published: (2014-04-01)

Trough level of infliximab is useful for assessing mucosal healing in Crohn's disease: a prospective cohort study
by: Akihiro Koga, et al.
Published: (2018-04-01)

Infliximab-related tubercular spinal epidural abscess without osseous involvement in a patient with Crohn’s disease: A case report
by: Phani Kiran Surapuraju, et al.
Published: (2021-01-01)

Crohn's Disease: General characteristics and treatment with Adalimumabe biopharmaceutical
by: S. A. Marques, et al.
Published: (2018-02-01)

Efficacy and safety of adalimumab in the treatment of Crohn's disease in children
by: Víctor Manuel Navas-López, et al.
Published: (2013-12-01)

Crohn’s Disease Associated Pyoderma Gangrenosum Treated with Adalimumab
by: Despoina Kakagia, et al.
Published: (2012-03-01)

CROHN'S DISEASE: GENERAL CHARACTERISTICS AND TREATMENT WITH ADALIMUMABE BIOPHARMACEUTICAL
by: S. A. Marques, et al.
Published: (2018-02-01)

Long-Term Clinical Outcomes of Korean Patient With Crohn's Disease Following Early Use of Infliximab
by: Nam Hee Kim, et al.
Published: (2014-10-01)

Hidradenitis Suppurativa as a Paradoxical Side Effect to the Use of Adalimumab in Patients with Crohn’s Disease?
by: Beraldo RF, et al.
Published: (2020-08-01)

Cortical Vein Thrombosis after Infliximab Treatment for Crohn’s Disease
by: Saeed Razmeh, et al.
Published: (2021-03-01)

Retreatment and maintenance therapy with infliximab in fistulizing Crohn' disease Retratamiento y tratamiento de mantenimiento con infliximab en la enfermedad de Crohn fistulizante
by: L. Rodrigo, et al.
Published: (2004-08-01)

The Montreal classification for Crohn's disease: clinical application to a Brazilian single-center cohort of 90 consecutive patients Classificação de Montreal para doença de Crohn: aplicação clínica em uma coorte brasileira de 90 pacientes consecutivos
by: Ulysses dos Santos Torres, et al.
Published: (2010-09-01)

Infliximab-induced intertriginous psoriasis in patient with Crohn's desease
by: Federica Mola, et al.
Published: (2011-10-01)

Doença de Crohn metastática sem manifestação clínica intestinal Metastatic Crohn's disease without intestinal clinical manifestation
by: Marcelo D&#8217;Ambrosio Fernandes, et al.
Published: (2009-12-01)

Cannot write session to /tmp/vufind_sessions/sess_8jsnfhvnqvufq462n6aigq642u